Vancomycin Dose Optimization in Obesity

NCT06601257

Status	RECRUITING
Phase	Phase 1
Sponsor	University of Michigan
Enrollment	24 participants

Key Eligibility Criteria

Inclusion (4)

- healthy obese participants within three obese class groups; BMI 30-34.9 kg/m2 (n=8), BMI 35-39.9 kg/m2 (n=8), and BMI e 40 kg/m2 (n=8)
- Male or female adults age 18 to 50 years
- Weight e 80 kg
- Estimated creatinine clearance of 60 mL/min to 119 mL/min (n=12) or e 120 mL/min (n=12) (based on the Cockcroft-Gault equation and dosing weight)

Exclusion (15)

- Pregnant or lactating females
- Significant clinical illness within 3 weeks prior to screening
- History of severe allergic diseases including drug allergies, with the exception of seasonal allergies
- Patients initiated on GLP1 agonists
- Any other factor, condition, or disease, including but not limited to cardiovascular, renal, hepatic, or gastrointestinal disorders that may, in the opinion of the Investigator, jeopardize the safety of the participant or impact the validity of the study results.

... and 10 more (see full listing online)

Locations (1 total)

Michigan Clinical Research Unit, Ann Arbor, Michigan, United States